Research
As a practice we support research studies.
During 2023/2024 Heswall & Pensby Group Practice recruited 865 participants to 5 NHS research studies.
NOTE – If you do not want to be contacted with regards to invite to research studies that you might be eligible for, please inform the practice.
LAKI Alzheimer’s study
TRAILRUNNER-ALZ 3 is a clinical research study from Eli Lilly and Company. It is testing if an investigational medicine may help treat people who might have early
Alzheimer’s disease or might be at risk of developing symptoms of Alzheimer’s disease. An investigational medicine is a medicine that is being studied to treat a certain health condition.
Further further information, please email – cmicb-wi.researchmlmp@nhs.net
6.12 LAKI_Flyer_Master_v1_19Aug2024_UK-EN
NOVA 301 – STUDY CLOSED
The trial evaluates the efficacy and safety of a norovirus vaccine called mRNA-1403. There are currently no licensed norovirus vaccines in use anywhere in the world.
The Phase 3 trial will take place at 39 sites across the country. This includes 27 NHS primary and secondary care sites. It aims to recruit 2,500 participants in the UK between late October and early 2025.
Participants will be randomly assigned to two groups. Half will receive the investigational norovirus vaccine and the other half will receive a placebo. Anyone 18 years or older who meets all the inclusion criteria is eligible for the trial. But researchers are seeking participants 60 years of age and older. This older age group of people is generally more likely to be severely affected by norovirus. Any future vaccine would benefit them most.
TRIUMPH
The TRIUMPH-OUTCOMES study will test if the investigational medicine can help reduce the risk for heart disease and slow down the development of kidney disease in people with excess weight.
If you decide to take part in the TRIUMPH-OUTCOMES study, you will be randomly assigned (that is by chance) to get either the investigational medicine or placebo. You will give yourself an injection of the study medicine once a week using a prefilled single-dose pen.
For further information, please read the attached brochure.
To sign up scan visit www.futuremeds.co.uk or call 0151 315 0090.
DaRe 2 THINK
Our surgery is taking part in a research study for patients who have had a heart rhythm problem called atrial fibrillation (AF).
The aim of this NHS study is to see whether patients who have had AF would benefit from receiving blood thinners earlier than they would usually receive. Blood thinners are commonly used in patients at high risk to prevent strokes and blood clots. Patients with AF also have a high risk of developing dementia. Newer blood thinners (direct oral anticoagulants) could help to prevent cognitive decline (trouble remembering, concentrating or making everyday decisions) that lead to dementia.
This study, DaRe2THINK, is being run in GP surgeries across the NHS in England. The trial uses a new system that means you do not have to visit your doctor or the hospital. You can enter the study by talking with your GP or practice staff on the phone, and completing short forms on your mobile phone, tablet or computer Please read the attached information sheet for more details. You can see a video that outlines the study at https://youtu.be/KLYZTZk4Kmc
If you are interested in taking part in DaRe2THINK then you can:
1) Go to this webpage for more information and to request a call back from a member of the research team: https://redcap.link/d2t
2) Contact Heswall & Pensby Group Practice at your GP surgery by telephone and request to speak with Dr Forster.
Victorion
The Victorion research study aims to find out if the study treatment, called Inclisiran, can help prevent cardiovascular events (such as heart attacks, strokes, procedures to improve blood flow, and death) in adults who are at high cardiovascular risk but have not had a major cardiovascular event, and who also have high cholesterol.
Click on the links below for further information
Prevail Generic Study Information Overview Sheet V2 07NOV2022 Clean
VICTORION-1 PREVENT_Patient information brochure_V1_23Feb23_English (UK)
Discover Me
E.mbrace
The E.mbrace Study will assess the effectiveness and safety of an investigational vaccine in the prevention of blood infections in adults aged 60 or over. These blood infections can lead to serious complications such as dangerously low blood pressure or shock.
Click for further info – Clinical trial: Blood Infection Research Study | Futuremeds
The FLASH Study
Although there are several treatment options already available for asthma, some individuals may still have difficulty controlling their symptoms.
Heswall and Pensby Surgery is taking part in the FLASH study which is investigating whether a medication called Atuliflapon can improve symptoms for patients
living with moderate to severe uncontrolled Asthma.
This study is recruiting male and female participants between the age of 18-55 years of age with a confirmed asthma diagnosis.
Heswall and Pensby Surgery is working with our research technology partner uMed to invite patients to this study. If you meet the study criteria, you may receive a text
message, email or letter asking whether you would like to take part. Participation is entirely voluntary and you can opt out at any time.
If you have any questions about this study please contact the uMed nurse support team at patientsupport@umed.io.
